

---

# COVID-19 Therapeutics Provider Webinar

**Hosted by:**

Greg Desrosiers Sr.

**Acknowledgements:**

CRRU Therapeutics Team

Amani Atallah, Dr. Andrea Lara, Dr. Richard Leman, Sydney Koweh,  
Leena Girdy, Tommy Mulroney, Colin Heintzeman, Drew Harper



# Agenda

- Welcome & Introductions
- COVID-19 Therapeutics Updates
  - Prescribing Guidance
  - Panelist Discussion
    - Q & A
- Closing Comments & Resources
  - Adjourn

# Speakers

**Greg Desrosiers Sr.**  
Oregon Health Authority,  
Outreach Coordinator

**Richard Leman, MD**  
Oregon Health Authority,  
Senior Health Advisor

**Jason Bradley**  
One Community Health Hood River,  
Site Director

**Roxanna Pascual**  
**Ian Clemons, PA-C**  
**Alejandro Lopez**  
**Matt Kelly, RN**  
**Daniel Alvarez-Vargas, PA-C**  
Virginia Garcia Memorial Health Center



# COVID-19 Therapeutics Updates



# New Developments

## **FDA authorizes State-licensed Pharmacists to Prescribe Paxlovid with Certain Limitations**

- EUA requires pharmacist to evaluate for severe kidney and liver disease, drug allergies, and interactions
- Requires access to recent medical records or consultation with clinician familiar with patient
- Requires access to full list of medications from clinician, pharmacy, or patient

# New Developments (cont.)

## Paxlovid Rebound

- Post-treatment increases in SARS-CoV-2 RNA shedding (i.e., viral RNA rebound) in nasopharyngeal samples observed in a subset of PAXLOVID and placebo recipients, irrespective of COVID-19 symptoms.
- The frequency of detection of post-treatment viral RNA rebound was **generally similar among PAXLOVID and placebo recipients**, regardless of the rebound definition used.
- Post-treatment viral RNA rebound wasn't associated with COVID-19-related hospitalization or death from any cause through Day 28 following Paxlovid treatment.

# Tixagevimab/Cilgavimab (Evusheld)

## Redosing

- Long-acting monoclonal antibody combo
- Used for prevention of COVID-19 in patients who
  - are moderately to severely immunocompromised, or
  - have medical contraindications to COVID-19 vaccines
- FDA recently authorized redosing at 6-month intervals

# Bebtelovimab

## Intravenous monoclonal antibody

- The USG ordered an additional **150,000 doses**
- For treatment of lab-confirmed COVID-19 in those at increased risk of severe illness, if started within 7 days of illness onset
- Limited data on clinical effectiveness
- *In vitro* activity against Omicron BA.4 and BA.5
- Shelf-life extensions authorized by the FDA



# Prescribing Guidance





# Prescribing Guidance

## NIH Guidelines for Therapeutic Management of Non-Hospitalized Adults with COVID-19

Does Not Require Hospitalization or Supplemental Oxygen

All patients should be offered symptomatic management (AIII).

For patients who are at high risk of progressing to severe COVID-19,<sup>a</sup> use 1 of the following treatment options:

**Preferred Therapies**  
*Listed in order of preference:*

- Ritonavir-boosted nirmatrelvir (Paxlovid)<sup>b,c</sup> (AIIa)
- Remdesivir<sup>c,d</sup> (BIIa)

**Alternative Therapies**  
*For use ONLY when neither of the preferred therapies are available, feasible to use, or clinically appropriate. Listed in alphabetical order:*

- Bebtelovimab<sup>e</sup> (CIII)
- Molnupiravir<sup>c,f</sup> (CIIa)

The Panel **recommends against** the use of dexamethasone<sup>g</sup> or other systemic corticosteroids in the absence of another indication (AIII).

**Rating of Recommendations:** A = Strong; B = Moderate; C = Weak

**Rating of Evidence:** I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb- Nonrandomized trials or observational cohort studies; III = Expert opinion

[NIH Therapeutic Management of Non-hospitalized Adults With COVID-19](#)



# Panel Discussion



# Panel Discussion



**Jason Bradley**  
Site Director, One  
Community Health  
Hood River




# Panel Discussion

## COVID-19 Response

- Performed 9,794 COVID tests with overall 10% positivity rate
- Since pandemic began, 14% positivity rate for Hispanic/Latinx versus 6% for non-Hispanic


ETHNIC_GROUP (groups)	INDETERMINATE OR INVALID	NEGATIVE	POSITIVE	Total
Hispanic	14	3808	625	4447
Non-Hispanic	17	4564	341	4922
Patient Refused & Uncollected & Unknown	2	389	33	424
<b>Total</b>	<b>33</b>	<b>8762</b>	<b>999</b>	<b>9794</b>

PATIENT_RACE	INDETERMINATE OR INVALID	NEGATIVE	POSITIVE	Total
Alaskan Native		10		10
American Indian	3	297	18	318
Asian		59	1	60
Black/African American		43	2	45
Native Hawaiian		3	1	4
Pacific Islander	2	36	3	41
Patient Refused	1	89	10	100
Uncollected	1	212	24	237
Unknown	1	186	22	209
White	25	7826	918	8769
<b>Total</b>	<b>33</b>	<b>8762</b>	<b>999</b>	<b>9794</b>




Oregon  
Health  
Authority

# Panel Discussion



## T2T Data

- Starting May 2022 53% of people seen are underserved
- 30% positivity for Hispanic/Latinx
- 15% for non-Hispanic



One Community Health



Oregon  
Health  
Authority

# One Community Health



## Outcome of T2T

- Reduction of PPE burden
- Updated access to testing and vaccines from a few days a week to daily
- Avoided sending patients to ED
- T2T staff increased capacity for PCP staff with inflow of migrant workers
- Educational social media posts, stickers on OTC test kits
- May positivity rate was 23% while Hood River and Wasco Counties are much lower
- Disproportionate positivity rates for people of color, 32/43 people who identify as Latinx tested positive

# Panel Discussion



Virginia Garcia Memorial  
**HEALTH CENTER**

**Roxanna Pascual**  
Regional Operations Manager

**Ian Clemons**  
Physician Assistant, PA-C

**Alejandro Lopez**  
Core Team Coordinator

**Matt Kelly, RN**  
Core Team

**Daniel Alvarez-Vargas**  
Physician Assistant, PA-C

<https://viriniagarcia.org/locations/hillsboro-clinics/>



# Virginia Garcia

## COVID-19 Data – 7th Avenue Location

Age Group	Immunizations	Tests	Positive Results	Treatments
<18	195	151	53	0
18-21	48	70	30	0
22-40	148	289	106	11
41-65	373	409	162	26
Over 65	205	89	34	8

Ethnic Group	Immunizations	Tests	Positive Results	Treatments
Hispanic	598	625	237	22
Non-Hispanic	273	297	120	20
Unknown	98	86	28	3



# Virginia Garcia

## Outcome of T2T

- Free take home tests, walk-ups, or by appointment testing and vaccines
- Take home kits with supplies and information about COVID-19
- Following mail distribution appointments doubled from 15-18 patients daily to 30 to 50 daily.
- Text message blast to patients, radio, updated website, flyers to CBOs, social media, signage at new facility
- Increase in:
  - Therapeutics to 3-4 patients a day.
  - Willingness to take therapeutic treatment (education still lacking)
  - COVID-19 positive patients

Without the OHA supported staff T2T would be non-operational



Testing site at Hillsboro 7<sup>th</sup> Ave Clinic



Registration area at Test to Treat site



# Q & A



Q & A

# OHA July Events

- **COVID-19 Therapeutics Monthly Newsletter** – Released July 8th
- **COVID-19 Community Therapeutics Webinars**
  - English – July 29<sup>th</sup> at 12:00pm – 1:00pm
    - Link:  
<https://www.zoomgov.com/meeting/register/vJlsduirrDwtHWego28W06qRIfks4V0cbY>
  - Spanish – July 29<sup>th</sup> at 1:30pm – 2:30pm
    - Link:  
[https://www.zoomgov.com/meeting/register/vJlsduChpjlgG9hWG5fck-Ow0vigqU\\_QnUk](https://www.zoomgov.com/meeting/register/vJlsduChpjlgG9hWG5fck-Ow0vigqU_QnUk)
- **July Logistics Office Hours**
  - Remaining Dates: July 18<sup>th</sup> and 25<sup>th</sup>
  - Every Monday from 2:00pm – 2:30pm
  - Link sent via GovDelivery Mondays and Fridays (standing invites coming soon!)

# We Love Feedback!

We have a quick pop-up poll on the screen. If you would kindly submit your responses, we'd love to hear about your experience.



**Question 1:** Did you find the updates provided in this webinar on the available COVID-19 therapeutics useful?

**Question 2:** With the information and resources provided, do you feel more comfortable prescribing therapeutics?

**Question 3:** What is one thing you would have wanted us to cover that was not discussed?

**Questions | Comments| Suggestions**

Email us: [OHA.therapeutics@dhsosha@state.or.us](mailto:OHA.therapeutics@dhsosha@state.or.us)

# Resources

- OHA Provider Monoclonal Antibodies webpage: [www.oregon.gov/oha/covid19/Pages/monoclonal-antibody-therapy.aspx](http://www.oregon.gov/oha/covid19/Pages/monoclonal-antibody-therapy.aspx)
- OHA Provider Antivirals webpage: [www.oregon.gov/oha/covid19/Pages/antivirals.aspx](http://www.oregon.gov/oha/covid19/Pages/antivirals.aspx)
- [OHA Logistics Office Hours](#)
- Evusheld EUA: <https://www.fda.gov/media/154701/download>
- Paxlovid EUA: <https://www.fda.gov/media/155050/download>
- Paxlovid Checklist  
<https://www.fda.gov/media/158165/download>
- Federal COVID-19 Therapeutics Clinical Implementation Guide: <https://aspr.hhs.gov/COVID-19/Therapeutics/Documents/USG-COVID19-Tx-Playbook.pdf>
- [CMS Reimbursement Info for mAbs](#)
- [CMS Reimbursement Info for Oral Antivirals](#)

# Summary of COVID-19 Therapeutics

